CN1304053C - Composition medicine for curing acute early-young granulocytic leukemia - Google Patents
Composition medicine for curing acute early-young granulocytic leukemia Download PDFInfo
- Publication number
- CN1304053C CN1304053C CNB031422381A CN03142238A CN1304053C CN 1304053 C CN1304053 C CN 1304053C CN B031422381 A CNB031422381 A CN B031422381A CN 03142238 A CN03142238 A CN 03142238A CN 1304053 C CN1304053 C CN 1304053C
- Authority
- CN
- China
- Prior art keywords
- atra
- medicine
- composition
- young
- acute promyelocytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a medicinal composition which can cure acute promyelocytic leukemia. Two kinds of medicine of ATRA and As2O3 are used cooperatively, and leukemia cell clone is eliminated by means of a combined chemotherapy method from two different angles of induced differentiation and induced death. Finally, the purpose of curing acute promyelocytic leukemia is achieved.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of cancer, relate in particular to a kind of composition of medicine of curing acute promyelocytic leukemia.
Background technology
The Therapeutic Method of acute promyelocytic leukemia (APL) mainly contains: the combined chemotherapy method that (1) is traditional, and use a kind of anthracene ring antitumor medicinal (as daunorubicin) and add the antimetabolite cytosine arabinoside, part A PL patient is alleviated fully.(2) the 20 later stages eighties in century began to use the oral inducing leukemia cell differentiation of all-trans-retinoic acid (ATRA) and treated APL, had obtained higher complete remission rate, and patient's Infant Mortality reduces.(3) begin in year by using arsenic trioxide (As surplus in the of nearly 10
2O
3) drip-feed induced apoptosis in leukemia cell lines and treat APL and all can reach higher complete remission rate to the recurrence APL of onset or anti-ATRA.
It is higher to use traditional chemical therapeutic method treatment (APL) Infant Mortality, and complete remission rate and long-term survival rate are all lower.With ATRA oral medication APL, though the higher easily recurrence of complete remission rate, and after the recurrence often to the ATRA resistance.As
2O
3The recurrence APL of drip-feed treatment onset or anti-ATRA is all effective, but still has Problems Concerning Their Recurrence.The long-term survival rate of above Therapeutic Method is relatively low, does not all reach the purpose of eliminating the leukaemia clone, can not cure acute promyelocytic leukemia.
Summary of the invention
The objective of the invention is to provides a kind of composition of medicine of curing acute promyelocytic leukemia from inducing differentiation and apoptosis-induced two different angles.
The present invention can cure the composition of medicine of acute promyelocytic leukemia, and this composition of medicine is by inducing differentiation and apoptosis-induced ingredients, and the medicine of inducing differentiation is ATRA, and apoptosis-induced medicine is As
2O
3, break up and apoptosis-induced two different angles from inducing, and remove to eliminate leukemic clone in conjunction with the method for combined chemotherapy, finally reach the purpose of curing acute promyelocytic leukemia.
The application of the invention composition of medicine reaches and alleviates the needed time fully and significantly shorten, and patient PML-RAR alpha fusion gene copy number decline multiple obviously improves, and does not have the recurrence survival rate and obviously improves, and does not have recurrence and obviously prolongs life cycle.
Description of drawings
Fig. 1 adopts the survival curve comparison diagram of composition of medicine of the present invention and prior art.
But Fig. 2 detects the result who adopts the PML-RAR alpha fusion protein in the composition of medicine accelerated degradation leukaemia of the present invention for Western blot.
The specific embodiment
The present invention can cure the composition of medicine of acute promyelocytic leukemia by use in conjunction ATRA and As
2O
3Two kinds of medicines break up and apoptosis-induced two different angles from inducing, and remove to eliminate leukemic clone in conjunction with the method for combined chemotherapy, finally reach and cure leukemic purpose.
Specific embodiments is with ATRA and As
2O
3In 4: 1 ratio administration, i.e. oral ATRA0.64mg/kg/d (every day early, middle and late each part vic), simultaneously drip-feed every day As
2O
30.16mg/kg/d, continue more than 3 hours.When the high leukocytic mass formed by blood stasis occurring, give chemotherapy, oral or combined chemotherapy (adding cytosine arabinoside) as daunorubicin with hydroxyurea.
As shown in table 1, use ATRA and As
2O
3Composition of medicine treatment APL and traditional alone ATRA and alone As
2O
3Relatively, reaching fully, alleviation (CR) needed time significantly shortens.
| Used medicine | Number of patients | Reach the CR required time | Integral dose | |||
| Median | Mean value ± STDEV | Scope | Scope | Median | ||
| ATRA | 19 | 40.5 | 40.2 ± 10.5 | 25-65 | 750-1950 | 1230 |
| As 2O 3 | 16 | 31 | 32.6 ± 3.5 | 28-38 | 235-380 | 285 |
| ATRA+As 2O 3 | 20 | 25.5 | 25.4 ± 5.0 | 18-35 | ATRA578-1200 As 2O 3100-300 | 810 210 |
| Reach the CR required time relatively: first group and second group is compared, second group and the 3rd group comparison of P=0.0498, first group and the 3rd group comparison of P=0.0030, P=0.0003 | ||||||
Table 1
As shown in table 2, use real-time quantitative RT-PCR technology for detection PML-RAR alpha fusion gene copy number, thereby judge the situation of leukaemia's load reduction, set of applications composite medicine group patient PML-RAR alpha fusion gene copy number decline multiple is apparently higher than alone ATRA and alone As
2O
3The patient.PML-RAR α DoseN represents the fusion copy number in the table.
| Group | Used medicine | Number of patients | PML-RAR α DoseN fusion copy number | ||
| Diagnostic period | After reaching CR | Consolidation | |||
| 1 | ATRA | 19 | (4595.6 1305.6～531249) | (793.5 37.5～26680) | (71.6 0.39～481.2) |
| 2 | As 2O 3 | 16 | (6655.7 1777.2～385317.9) | (286.3 19.1～13543) | (41.3 0.39～362.5) |
| 3 | ATRA+ As 2O 3 | 20 | (5155.3 1111.2～618050) | (177.3 0.7～389.9) | (15.2 0.03～252.4) |
| Fusion copy number absolute value respectively compares between group after reaching CR: ATRA and As 2O 3P=0.021 ATRA and ATRA+As 2O 3P=0.0092 As 2O 3With ATRA+As 2O 3P=0.041 | |||||
Table 2
See also the survivorship curve that Fig. 1 adopts composition of medicine of the present invention and prior art, the time after wherein abscissa represents to treat, ordinate represents not have recurrence survival rate, broken line ATRA+As
2O
3The survivorship curve of expression set of applications composite medicine group, broken line ATRA and broken line As
2O
3Represent respectively the oral and alone As of alone ATRA
2O
3The technical method of drip-feed.Figure as can be seen thus: the nothing recurrence survival rate of application combination medicine group obviously improves, and does not have recurrence and obviously prolongs life cycle.
PML-RAR alpha fusion protein in the set of applications composite medicine energy accelerated degradation leukaemia sees also the result that Fig. 2 Western blot tests, and the difference control group that shows from left to right adopts 0.1 μ M ATRA, adopts 0.1 μ M ATRA and 0.25 μ M As
2O
3Composition of medicine, adopt 0.25 μ M As
2O
3Process 8 hours result of APL cell.110KD represents the PML-RAR alpha fusion protein, and 71KD represents wild type PML albumen, also exists at normal cell.Figure can find out thus: set of applications composite medicine group patient PML-RAR alpha fusion gene copy number decline multiple is apparently higher than alone ATRA and alone As
2O
3The patient.
The present invention adopts and to induce differentiation and apoptosis-induced therapy to combine, and in conjunction with chemotherapy, when following up a case by regular visits to end in 15 months till, still do not have 1 routine Patients on Recurrence, overcome in the past alone chemotherapy or alone ATRA and alone As
2O
3The easy shortcoming of recurrence of methods for the treatment of, finally reach and eliminate leukemic clone and cure leukemic purpose.
Adopt composition of medicine treatment acute promyelocytic leukemia of the present invention to have following advantage:
(1) administrated method is simple, grasps easily and implements.ARTA is oral, simultaneously drip-feed every day As
2O
3
(2) use composition of medicine treatment APL of the present invention and reach and alleviate the needed time fully and significantly shorten, patient's nothing recurrence survival rate is significantly higher than alone ATRA and alone As
2O
3The patient, do not have recurrence and prolong life cycle.
(3) by the real-time quantitative RT-PCR scientific discovery, uses composition of medicine treatment APL of the present invention and reach and alleviate afterwards the leukaemia fully and load and descend more obviously.
(4) detect the PML-RAR alpha fusion protein by Western blot and find, the patient who uses composition of medicine treatment of the present invention degrades sooner.
Claims (1)
1, a kind of composition of medicine of curing acute promyelocytic leukemia is characterized in that this composition of medicine is by ATRA (ATRA) and As
2O
3Form, the dose application ratio of two kinds of medicines is ATRA: As
2O
3=4: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031422381A CN1304053C (en) | 2003-08-13 | 2003-08-13 | Composition medicine for curing acute early-young granulocytic leukemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031422381A CN1304053C (en) | 2003-08-13 | 2003-08-13 | Composition medicine for curing acute early-young granulocytic leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1579549A CN1579549A (en) | 2005-02-16 |
| CN1304053C true CN1304053C (en) | 2007-03-14 |
Family
ID=34579424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031422381A Expired - Fee Related CN1304053C (en) | 2003-08-13 | 2003-08-13 | Composition medicine for curing acute early-young granulocytic leukemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1304053C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106512230B (en) * | 2016-12-08 | 2018-11-09 | 吉林大学 | The device of blue light-all-trans retinoic acid-Nano diamond synergistic treatment leukaemia |
| CN112870225B (en) * | 2021-02-05 | 2023-01-06 | 北京大学人民医院 | Combination therapy medicine for induction phase of high-risk acute promyelocytic leukemia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1285743A (en) * | 1997-11-10 | 2001-02-28 | 斯隆－凯特林纪念癌症中心 | Process for production of arsenic trioxide formulations and methods for treating cancer using arsenic troxide or melarsoprol |
-
2003
- 2003-08-13 CN CNB031422381A patent/CN1304053C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1285743A (en) * | 1997-11-10 | 2001-02-28 | 斯隆－凯特林纪念癌症中心 | Process for production of arsenic trioxide formulations and methods for treating cancer using arsenic troxide or melarsoprol |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1579549A (en) | 2005-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021068614A1 (en) | Application of honokiol and magnolol in preparing mcr-1 enzyme inhibitor | |
| Bartkoski et al. | Alpha-lipoic acid for treatment of diabetic peripheral neuropathy | |
| Belknap et al. | The effects of psyllium hydrophilic mucilloid on diarrhea in enterally fed patients | |
| CN1304053C (en) | Composition medicine for curing acute early-young granulocytic leukemia | |
| CN111529671B (en) | New application of bupleurum tenue granules in combination with antibiotics | |
| CN101062029A (en) | Application of wogonin in the preparing of medicine for treating gastric cancer | |
| CN105853449B (en) | A kind of antibacterial compound drug of amikacin sulfate for injection | |
| CN109730983A (en) | Application of the rhapontigenin in preparation treatment medication for treating pyemia | |
| CN1814100A (en) | Medicine for treating and preventing vein injuries resulted from chemical medicine | |
| Taylor et al. | Bronchodilators and bronchial hyperresponsiveness. | |
| CN1660256A (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| DE60203895T2 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE MANUFACTURE OF A MEDICAMENT FOR SUPPRESSING THE SIDE EFFECTS OF RADIOTHERAPY AND CHEMOTHERAPY | |
| CN114831312B (en) | Traditional Chinese medicine composition composed of ganoderma lucidum polysaccharide and cicada fungus polysaccharide and application thereof | |
| CN1165331C (en) | Chinese medicine for treating tuberculosis | |
| CN1053817C (en) | Acanthopanax root injection freeze-dried powder injection and producing technology for acanthopanax root extract | |
| CN1293881C (en) | Compound antitussive | |
| US20230133657A1 (en) | The use of menthol for the preparation of a topical composition to improve neurodegenerative disease and stroke | |
| El Bethel Lalthavel Hmar et al. | An Insight into the Combination of Probiotics and their Implications for Human Health | |
| CN1209113C (en) | Tincture for treating psoriasis | |
| CN101062292A (en) | Medicine for treating cancer and preventing lung cancer and preparing method thereof | |
| Eichhorst et al. | Comparison of the Efficacy and Toxicity of Fludarabine (F) in First Line Therapy of Younger Versus Elderly Patients (Pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Meta-Analysis of Two Phase III Trials of the German CLL Study Group (GCLLSG). | |
| Zhou et al. | Understanding and Treatment of Peripheral Neurotoxicity Induced by Chemotherapy | |
| CN1943573A (en) | Use of vitamin C and arginine composition in anti-anoxic medicine and health product | |
| Jiang et al. | P0890 EFFICACY AND SAFETY OF CINACALCET IN CHINESE MAINTENANCE HEMODIALYSIS PATIENTS WITH DIFFERENT STAGES OF SECONDARY HYPERPARATHYROIDISM: INTERIM ANALYSIS RESULTS OF ACTIVE STUDY | |
| CN117224658A (en) | Pharmaceutical preparation for treating immunosuppression after acute ischemic cerebral apoplexy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070314 Termination date: 20100813 |